Trial Profile

PRIMIER:Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI-724 as First Line Treatment for Metastatic Colorectal Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Foscenvivint (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms PRIMIER

Most Recent Events

13 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Study drug supply issues.
24 Sep 2015 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018 as reported by ClinicalTrials.gov.
24 Sep 2015 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com